Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors

Journal of Virology

Volumn 75, Issue 16, 2001, Pages 7266-7279

  Wang, D ^a   De La Fuente, C ^a   Deng, L ^a   Wang, L ^a   Zilberman, I ^a   Eadie, C ^a   Healey, M ^a   Stein, D ^a   Denny, T ^a   Harrison, L E ^a   Meijer, L ^a   Kashanchi, F ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIVIRUS AGENT; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; HYDROXYUREA; LIPOCORTIN 5; NOCODAZOLE; PROTAMINE KINASE; PROTEIN P21; ROSCOVITINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; SYNCYTIUM; TRANSCRIPTION REGULATION; VIRION; VIRUS PARTICLE; VIRUS STRAIN; VIRUS TRANSCRIPTION;

CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDES; PURINES; VIRUS REPLICATION;

EID: 0034910933     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.16.7266-7279.2001     Document Type: Article

References (52)

1. Morphological and biochemical characterization and analysis of apoptosis
2. Regulatory mechanisms of poly(ADP-ribose) polymerase
3. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
4. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication
5. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes
6. 1/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1
7. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone
8. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II
9. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone
10. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line
11. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
12. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
13. Upregulation of cyclin T1/CDK9 complexes during T cell activation
14. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo
15. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells
16. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
17. ATP-site directed inhibitors of cyclin-dependent kinases
18. Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines
19. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity
20. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase
21. Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines
22. Cyclins and cell cycle checkpoints
23. Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator
24. Electroporation of viral transactivator proteins into lymphocyte suspension cells
25. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus
26. Human immunodeficiency virus infection of cells arrested in the cell cycle
27. Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells
28. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
29. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes
30. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds
31. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
32. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases
33. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity
34. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation
35. Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
36. Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: Distinct patterns of viral growth are determined by T-cell types
37. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription
38. Transcription of herpes simplex virus immediate-early and early genes is inhibited by Roscovitine, an inhibitor specific for cellular cyclin-dependent kinases
39. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins
40. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins
41. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I Science
42. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro
43. Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent
44. + T cells are infectible by human immunodeficiency virus but do not release virus after activation
45. Characterization of the residues phosphorylated in vitro by different C-terminal domain kinases
46. Specific tropism of HIV-1 for microglial cells in primary human brain cultures
47. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA
48. Productive human immunodeficiency virus type 1 (HIV-1) infection of non-proliferating human monocytes
49. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
50. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription
51. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro